motixafortide — Interim data
2026
A prespecified interim/futility analysis is planned when 40% of progression-free survival (PFS) events are observed, which the Company continues to anticipate will occur in 2026.Source filing
BLRX biotech catalysts & pipeline
BIOLINERX LTD · Data as of 2026-09-08
Upcoming catalysts
GLIX1 — Interim data
H2 2026
Updates to the Phase 1/2a trial are anticipated during H2 2026, with full results on the dose escalation part expected in 2027.Source filing
GLIX1 — Topline data
H1 2027
Data from the Phase 1 part of the trial are anticipated in H1 2027.Source filing
GLIX1 — Conference presentation
Sep 24–Sep 27
Clinical and pre-clinical data has been accepted for publication at the European Association of Neuro-Oncology (EANO) 2026 Conference and at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting.Source filing
GLIX1 — Conference presentation
Oct 23–Oct 27
An abstract featuring new GLIX1 data, demonstrating synergy with PARP inhibitors in HR-proficient ovarian cancer, was accepted for publication at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026) in October.Source filing
GLIX1 — Conference presentation
Nov 12–Nov 15
Clinical and pre-clinical data has been accepted for publication at the European Association of Neuro-Oncology (EANO) 2026 Conference and at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting.Source filing